CGS Stock Overview
Cogstate Limited, a cognitive science company, provides computerized cognitive tests for clinical trials, academic research, healthcare, and brain health applications in Australia and internationally.
Price History & Performance
|Historical stock prices|
|Current Share Price||AU$2.16|
|52 Week High||AU$2.49|
|52 Week Low||AU$0.80|
|1 Month Change||-9.24%|
|3 Month Change||27.43%|
|1 Year Change||121.54%|
|3 Year Change||232.31%|
|5 Year Change||96.36%|
|Change since IPO||332.00%|
Recent News & Updates
We Think Some Shareholders May Hesitate To Increase Cogstate Limited's (ASX:CGS) CEO Compensation
Performance at Cogstate Limited ( ASX:CGS ) has been reasonably good and CEO Brad O'Connor has done a decent job of...
|CGS||AU Healthcare Services||AU Market|
Return vs Industry: CGS exceeded the Australian Healthcare Services industry which returned 58.3% over the past year.
Return vs Market: CGS exceeded the Australian Market which returned 11.8% over the past year.
|CGS Average Weekly Movement||8.2%|
|Healthcare Services Industry Average Movement||8.5%|
|Market Average Movement||8.3%|
|10% most volatile stocks in AU Market||15.8%|
|10% least volatile stocks in AU Market||3.7%|
Stable Share Price: CGS is not significantly more volatile than the rest of Australian stocks over the past 3 months, typically moving +/- 8% a week.
Volatility Over Time: CGS's weekly volatility (8%) has been stable over the past year.
About the Company
Cogstate Limited, a cognitive science company, provides computerized cognitive tests for clinical trials, academic research, healthcare, and brain health applications in Australia and internationally. The company’s services include project management, data management, scientific consulting, statistical analysis, scales procurement, rater training, and monitoring solutions. It operates in Clinical Trials and Healthcare segments.
Cogstate Fundamentals Summary
|CGS fundamental statistics|
Is CGS overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|CGS income statement (TTM)|
|Cost of Revenue||US$15.21m|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
|Earnings per share (EPS)||0.03|
|Net Profit Margin||16.01%|
How did CGS perform over the long term?See historical performance and comparison
Is Cogstate undervalued compared to its fair value and its price relative to the market?
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: CGS (A$2.16) is trading above our estimate of fair value (A$1.72)
Significantly Below Fair Value: CGS is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: CGS is good value based on its PE Ratio (50.7x) compared to the Global Healthcare Services industry average (56.4x).
PE vs Market: CGS is poor value based on its PE Ratio (50.7x) compared to the Australian market (18.7x).
Price to Earnings Growth Ratio
PEG Ratio: CGS is poor value based on its PEG Ratio (1.5x)
Price to Book Ratio
PB vs Industry: CGS is overvalued based on its PB Ratio (12.2x) compared to the AU Healthcare Services industry average (4.4x).
How is Cogstate forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: CGS's forecast earnings growth (33.8% per year) is above the savings rate (1.9%).
Earnings vs Market: CGS's earnings (33.8% per year) are forecast to grow faster than the Australian market (11.6% per year).
High Growth Earnings: earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: CGS's revenue (22.2% per year) is forecast to grow faster than the Australian market (5.2% per year).
High Growth Revenue: CGS's revenue (22.2% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if CGS's Return on Equity is forecast to be high in 3 years time
How has Cogstate performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: CGS has a large one-off gain of $2.4M impacting its June 30 2021 financial results.
Growing Profit Margin: CGS became profitable in the past.
Past Earnings Growth Analysis
Earnings Trend: CGS has become profitable over the past 5 years, growing earnings by 6.2% per year.
Accelerating Growth: CGS has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: CGS has become profitable in the last year, making it difficult to compare its past year earnings growth to the Healthcare Services industry (33.1%).
Return on Equity
High ROE: CGS's Return on Equity (24%) is considered high.
How is Cogstate's financial position?
Financial Position Analysis
Short Term Liabilities: CGS's short term assets ($34.1M) exceed its short term liabilities ($18.9M).
Long Term Liabilities: CGS's short term assets ($34.1M) exceed its long term liabilities ($10.7M).
Debt to Equity History and Analysis
Debt Level: CGS is debt free.
Reducing Debt: CGS had no debt 5 years ago.
Debt Coverage: CGS has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: CGS has no debt, therefore coverage of interest payments is not a concern.
What is Cogstate current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate CGS's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate CGS's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if CGS's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if CGS's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of CGS's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Mr. Bradley O'Connor, also known as Brad, B.Bus, CA, has been the Chief Executive Officer and Managing Director of Cogstate Limited since December 1, 2005 and served as its Chief Financial Officer since Ma...
CEO Compensation Analysis
Compensation vs Market: Brad's total compensation ($USD1.08M) is above average for companies of similar size in the Australian market ($USD553.04K).
Compensation vs Earnings: Brad's compensation has been consistent with company performance over the past year.
Experienced Management: CGS's management team is not considered experienced ( 1.1 years average tenure), which suggests a new team.
Experienced Board: CGS's board of directors are considered experienced (6.4 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: CGS insiders have sold more shares than they have bought in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Cogstate Limited's employee growth, exchange listings and data sources
- Name: Cogstate Limited
- Ticker: CGS
- Exchange: ASX
- Founded: 1999
- Industry: Health Care Technology
- Sector: Healthcare
- Market Cap: AU$369.368m
- Shares outstanding: 172.60m
- Website: https://www.cogstate.com
Number of Employees
- Cogstate Limited
- 425 Smith Street
- Suite 117
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/11/29 07:03|
|End of Day Share Price||2021/11/29 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.